Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
iTeos Therapeutics (ITOS)
NASDAQ:ITOS
iTeos Therapeutics (ITOS) Stock Price & Analysis
154 Followers
ITOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.20 - $18.75
Previous Close$14.78
Volume386.72K
Average Volume (3M)438.44K
Market Cap
$515.84M
Enterprise Value$90.58M
Total Cash (Recent Filing)$449.14M
Total Debt (Recent Filing)$5.82M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 07, 2024EPS Estimate
-$1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.78
Shares Outstanding36,122,922
10 Day Avg. Volume437,264
30 Day Avg. Volume438,444
Standard Deviation0.20
R-Squared0.13
Alpha-0.00122
Financial Highlights & Ratios
Price to Book (P/B)0.99
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.19
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$33.50Price Target Upside134.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
iTeos Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ITOS FAQ
What was iTeos Therapeutics’s price range in the past 12 months?
iTeos Therapeutics lowest stock price was $8.20 and its highest was $18.75 in the past 12 months.
What is iTeos Therapeutics’s market cap?
Currently, no data Available
When is iTeos Therapeutics’s upcoming earnings report date?
iTeos Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 33 days.
How were iTeos Therapeutics’s earnings last quarter?
iTeos Therapeutics released its earnings results on May 10, 2024. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.982 by -$0.088.
Is iTeos Therapeutics overvalued?
According to Wall Street analysts iTeos Therapeutics’s price is currently Undervalued.
Does iTeos Therapeutics pay dividends?
iTeos Therapeutics does not currently pay dividends.
What is iTeos Therapeutics’s EPS estimate?
iTeos Therapeutics’s EPS estimate is -$1.04.
How many shares outstanding does iTeos Therapeutics have?
iTeos Therapeutics has 36,122,920 shares outstanding.
What happened to iTeos Therapeutics’s price movement after its last earnings report?
iTeos Therapeutics reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.982. Following the earnings report the stock price went up 43.068%.
Which hedge fund is a major shareholder of iTeos Therapeutics?
Among the largest hedge funds holding iTeos Therapeutics’s share is RA Capital Management. It holds iTeos Therapeutics’s shares valued at 60M.
---
iTeos Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.50 (134.59% Upside)
$33.50 (134.59% Upside)
Blogger Sentiment
Bullish
ITOS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 14.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.62%
12-Months-Change
Fundamentals
Return on Equity
-22.67%
Trailing 12-Months
Asset Growth
-13.53%
Trailing 12-Months
Company Description
iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
---
ITOS Stock 12 Month Forecast
Average Price Target
$33.50
▲(134.59% Upside)
Technical Analysis
Best Analysts Covering ITOS
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-6.15%
reiterated a buy rating 4 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -6.15% per trade.
---